Recruiting

UCRI Biomarker Panel

Sponsor:

Glycominds, LLC

Code:

NCT04897282

Conditions

Ulcerative Colitis

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

UCRI

Study Details

Brief summary:

The purpose of this research study is to determine the efficacy and outcome of the UCRI (an in-vitro diagnostics device in the form of a blood test and an algorithm) as a tool to detect mucosal healing (level of inflammation in the colon) in people with moderate-to-severe ulcerative colitis treated with anti-TNFα. Another reason is to explore additional biomarkers in blood, stool or voice to detect disease activity and/or mucosal healing. A tool to detect the level of inflammation in the colon based on blood, stool or voice biomarkers may reduce the need or the number of invasive endoscopic procedures. This is an observational study and no treatment decision nor clinical intervention will be done based on results during this study and all collected data will be used only for the goal of the study and for obtaining FDA IDE for a follow-up study.

Conditions

Ulcerative Colitis

Study ID

NCT04897282

Start date

Aug 24, 2021

Status verified date

Aug, 2023

Completion date

Dec 31, 2024

Anticipated

Primary completion date

Dec 31, 2024

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Ulcerative colitis patients with Mayo Endoscopic Subscore of 2-3
  • Start/switch anti -TNFa treatment
  • Capable of at-home fCal testing

Exclusion Criteria:

  • Pregnant women
  • anti -TNFa dose escalation/adjustment
  • Inability to undergo endoscopic assessments due to Proctitis
  • Diagnosed with infectious diseases
  • Steroid refractory

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Interventions

UCRI

Biomarker panel and algorithm

Primary outcome measure

  • UCRI panel validation [ Time Frame: 24 weeks ]
  • UCRI panel validation [ Time Frame: 24 weeks ]
  • UCRI panel validation [ Time Frame: 24 weeks ]

Central Contacts and Locations

Central contacts

Avinoam A Dukler, PhD

8057912094ucri@glycominds.com

Locations

UC Davis Inflammatory Bowel Disease Center

Recruiting

Sacramento, California, United States, 95816

Contacts

Principal Investigator:

Eric J Mao, MD

More Information

Sponsor

Glycominds, LLC

Last update posted

Aug 18, 2023

Last verified

Aug, 2023

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Glycominds, LLC on 2023-08-18.